# AstraZeneca - Career and AI Safety Context
> Last updated: 2026-02-20 by Claude (from claude.ai memory export)

## Key Facts
- [[ALTON]] is Medical Director, AI Innovation and Validation, Global Patient Safety
- Prospect: Senior Medical Director (NYC Empire State Building, posting closed Feb 16, 2026)
- Delaware office (remote 2 days/week from Montclair, 3 days/week on-site, 125 mi each way)
- Previous AZ role: Medical Director of Device & Digital Safety
- OpenAI Red Teaming Network member; Anthropic partnership lead at AZ

## Current Role Details

**Title:** Medical Director, AI Innovation and Validation
**Division:** Global Patient Safety (Pharmacovigilance)
**Location:** Delaware office (remote 2 days/week from Montclair, NJ)
**Commute:** 125 miles each way, 3 days/week on-site — described as exhausting

**Core Responsibilities:**
- Leading AI-native drug development initiatives
- Predictive safety platforms for cell therapy AEs (CRS/ICANS prediction)
- Building strategic partnerships with frontier AI labs (OpenAI, Anthropic, Google)
- AI/ML clinical validation oversight
- Regulatory agency engagement (FDA, EMA)

**Promotion Prospect:**
- Senior Medical Director, AI Innovation and Validation, Global Patient Safety
- Location: New York City (Empire State Building)
- Posting closed: Feb 16, 2026
- Salary range: $288,059.20 - $432,088.80 + equity + bonus
- Requirements: MD + 5-7+ years PV experience

## Strategic Work at AZ

- Developing comprehensive AI-native drug development frameworks for AZ C-suite leadership
- Positioning external AI lab partnerships as mandatory (not optional) for competitive advantage
- Framing AI transformation as a foundational shift, not a tooling upgrade
- Natural history studies: NMDA receptor abnormalities in tuberous sclerosis complex and focal cortical dysplasia
- Research: GRIN gene variants in neurodevelopmental disorders

## AI Industry Engagements

**OpenAI:**
- Member of the Red Teaming Network
- Contributions acknowledged in GPT-4o system card

**Anthropic:**
- Developing strategic partnership at AstraZeneca level
- Led workshops with Anthropic teams on custom patient safety agents

**Google:**
- Participated in Google Cancer AI Symposium

## AZ Internal AI Tools

**MILTON:**
- Disease prediction model using 67 biomarkers
- AUC > 0.7 for 1091 diseases

**JARVIS:**
- Non-coding variant pathogenicity prediction
- Genomics-focused AI tool

## Pharmacovigilance AI Frameworks

**Signal Detection:**
- Traditional: PRR, ROR
- Bayesian: BCPNN, MGPS
- ML-enhanced: Gradient Boosted Models (sensitivity 0.92), Deep Learning (>95% accuracy)
- Ensemble approaches

**NLP for Safety:**
- ADR extraction from literature
- Social media monitoring
- Clinical trial narrative analysis
- Automated case processing and triage

## Career Context
- Alton has experienced delays in promotion despite expertise at intersection of neurology and AI
- Actively exploring external roles (chief safety officer at AI companies)
- Commute burden is a persistent dissatisfier
- The NYC Senior Director role would significantly improve commute and career trajectory

## Important Dates
- **March 15, 2026:** AZ March Bonus
- **Feb 16, 2026:** NYC Senior Director posting closed

## Open Questions
- When does Alton officially start in the new role (if confirmed)?
- Who does he report to?
- Hybrid vs in-office schedule for NYC role?
- Key first-quarter deliverables?

## Related
- [[BUSINESS]] - Business context and strategy for pharma work
- [[PROJECTS]] - Project tracking (esp. safety-research-system)
- [[LEARNINGS]] - Lessons learned from AI/ML work

## History
- 2026-02-06: Initial creation based on background research
- 2026-02-20: Major update from claude.ai memory export — AI industry engagements (OpenAI/Anthropic/Google), strategic work, career frustrations, commute details, previous role
